Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
Authors
Keywords
-
Journal
Expert Opinion on Orphan Drugs
Volume 5, Issue 4, Pages 369-374
Publisher
Informa UK Limited
Online
2016-11-04
DOI
10.1080/21678707.2016.1256768
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The safety of treatment options for elderly people with acute myeloid leukemia
- (2016) Xavier Thomas et al. Expert Opinion On Drug Safety
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging therapeutic drugs for AML
- (2015) E. M. Stein et al. BLOOD
- Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
- (2015) D. Grimwade et al. BLOOD
- Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions
- (2015) David Sanford et al. DRUGS & AGING
- Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
- (2015) Edgar Pérez-Herrero et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition
- (2015) M. W. M. Kuhn et al. HAEMATOLOGICA
- Sorafenib and novel multikinase inhibitors in AML
- (2015) Naval Daver et al. LANCET ONCOLOGY
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
- (2015) Farhad Ravandi et al. LANCET ONCOLOGY
- Design considerations for nanotherapeutics in oncology
- (2015) Triantafyllos Stylianopoulos et al. Nanomedicine-Nanotechnology Biology and Medicine
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Why Is Progress in Acute Myeloid Leukemia So Slow?
- (2015) Elihu Estey SEMINARS IN HEMATOLOGY
- MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition
- (2015) M. W. M. Kuhn et al. HAEMATOLOGICA
- Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?
- (2014) Farhad Ravandi BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
- (2014) J. E. Lancet et al. BLOOD
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
- (2014) H. Dohner et al. BLOOD
- How I treat the older patient with acute myeloid leukemia
- (2014) G. Ossenkoppele et al. BLOOD
- Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis
- (2014) M. Tan et al. BLOOD
- Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
- (2014) Jorge E. Cortes et al. CANCER
- Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls
- (2014) Hideaki Nakamura et al. Expert Opinion on Drug Delivery
- Post-remission therapy for acute myeloid leukemia
- (2014) R. F. Schlenk HAEMATOLOGICA
- Development of Liposomal Anticancer Drugs
- (2013) Kenji Hyodo et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute myeloid leukaemia in adults
- (2013) Felicetto Ferrara et al. LANCET
- The impact of mutational profiling on AML prognosis
- (2012) Jacob M. Rowe BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Survival for older patients with acute myeloid leukemia: a population-based study
- (2012) B. Oran et al. HAEMATOLOGICA
- Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
- (2012) E.J. Feldman et al. LEUKEMIA RESEARCH
- Therapeutic Advances in Acute Myeloid Leukemia
- (2011) Alan Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
- (2011) Eric J. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- How I treat acute myeloid leukemia
- (2010) J. M. Rowe et al. BLOOD
- Questions regarding frontline therapy of acute myeloid leukemia
- (2010) Hagop Kantarjian et al. CANCER
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts
- (2010) Wah-Seng Lim et al. LEUKEMIA RESEARCH
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
- (2008) Paul Tardi et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More